FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 62-68

  Garrido, W ^a   Munoz M ^a   San Martin R ^a   Quezada, C ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

FK506; Glioblastoma multiforme; Mrp1; Multiple resistance drugs

Indexed keywords

ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TACROLIMUS; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TACROLIMUS;

EID: 79960566297     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.087     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J. Clin. 2008, 58:71-96.
2. Clarke J., Butowski N., Chang S. Recent advances in therapy for glioblastoma. Arch. Neurol. 2010, 67:279-283.
3. Lu C., Shervington A. Chemoresistance in gliomas. Mol. Cell. Biochem. 2008, 12:71-80.
4. Quezada C., Peigñan L., Segura R., et al. Study of resistance to chemotherapy mediated by abc transporters in biopsies of glioblastoma. Rev. Med. Chile 2011, 139:415-424.
5. Sharom F.J. ABC multidrug transporters: structure function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.
6. Baguley B.C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 2010, 46:308-331.
7. Shukla S., Wu C.P., Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin. Drug Metab. Toxicol. 2008, 4:205-223.
8. L. Peigñan, W. Garrido, R. Segura, et al., Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro, Neurochem. Res., in press, doi: doi:10.1007/s11064-011-0464-8.
9. Calatozzolo C., Gelati M., Ciusani E., et al. Expression of drug resistance proteins Pgp MRP1 MRP3 MRP5 and GST-pi in human glioma. J. Neurooncol. 2005, 74:113-121.
10. Declèves X., Amiel A., Delattre J.Y., et al. Role of ABC transporters in the chemoresistance of human gliomas. Curr. Cancer Drug Targets 2006, 6:325-331.
11. Decleves X., Fajac A., Lehmann-Che J., et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 2002, 98:173-180.
12. Matsumoto Y., Miyake K., Kunishio K., et al. Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J. Med. Invest. 2004, 51:194-201.
13. Natazuka T. FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. Kobe. J. Med. Sci. 1992, 38:347-363.
14. Mizuno K., Furuhashi Y., Misawa T., et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues FK506 and mizoribine. Anticancer Res. 1992, 12:21-25.
15. Naito M., Oh-hara T., Yamazaki A., et al. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol. 1992, 29:195-200.
16. Gupta A., Dai Y., Vethanayagam R.R., et al. Cyclosporin A tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol. 2006, 58:374-383.
17. Quezada C.A., Garrido W.X., Gonzalez-Oyarzún M.A., et al. Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. Biol. Pharm. Bull. 2008, 31:1911-1916.
18. Kuypers D.R., Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration mean residence time and acute renal allograft rejection: an open-label prospective pharmacokinetic study in adult recipients. Clin. Ther. 2004, 26:1834-1844.
19. Mellor H.R., Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008, 81:275-300.
20. Arceci R.J., Stieglitz K., Bierer B.E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992, 80:1528-1536.
21. Leather H., Boyette R.M., Tian L., et al. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2006, 12:325-334.
22. Takahashi K., Yano I., Fukuhara Y., et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab. Pharmacokinet. 2007, 22:441-444.
23. Takeuchi H., Matsuno N., Senuma K., et al. Evidence of different pharmacokinetics including relationship among AUC peak and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter - why cyclosporine is monitored by C2 level and tacrolimus by trough level. Biol. Pharm. Bull. 2008, 31:90-94.
24. Lee S.W., Kim W.J., Park J.A., et al. Blood-brain barrier interfaces and brain tumors. Arch. Pharm. Res. 2006, 29:265-275.
25. Gekeler V., Ise W., Sanders K.H., et al. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 1995, 208:345-352.
26. Pawarode A., Shukla S., Minderman H., et al. Differential effects of the immunosuppressive agents cyclosporin A tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 2007, 60:179-188.
27. Donmez Y., Akhmetova L., Iseri O.D., et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother. Pharmacol. 2011, 67:823-828.
28. Kweon S.H., Song J.H., Kim T.S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem. Biophys. Res. Commun. 2010, 395:104-110.
29. Zhu F.S., Chen X.M., Huang Z.G., et al. Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. J. Dig. Dis. 2010, 11:34-42.
30. O'Connor R., Heenan M., Connolly L., et al. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res. 2004, 24:457-464.
31. O'Connor R., O'Leary M., Ballot J., et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol. 2007, 59:79-87.
32. Duffy C.P., Elliott C.J., O'Connor R.A., et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34:1250-1259.
33. Davies N., Watson M. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin. Pharmacokinet. 1997, 32:437-459.
34. Robey R.W., Shukla S., Finley E.M., et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor CBT-1((R)). Biochem. Pharmacol. 2008, 75:1302-1312.
35. Peck R.A., Hewett J., Harding M.W., et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 2001, 19:3130-3141.
36. Stupp R., van den Bent M.J., Hegi M.E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr. Neurol. Neurosci. Rep. 2005, 5:198-206.
37. Hegi M.E., Liu L., Herman J.R., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26:4189-4199.
38. Brada M., Stenning S., Gabe R., et al. Temozolomide versus procarbazine lomustine and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 2010, 28:4601-4608.